Trial Profile

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edaravone (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Registrational
Acronyms ADOREXT
Sponsors Ferrer

Most Recent Events

17 Mar 2024 This trial has been completed in Sweden (Global end date: 22 Feb 2024).
08 Mar 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
13 Feb 2024 Status changed from recruiting to discontinued. (After the analysis of the main ADORE study it is concluded that there is no clinical benefitfor the patients.)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com